Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT

被引:31
作者
Parkkali, T [1 ]
Stenvik, M [1 ]
Ruutu, T [1 ]
Hovi, T [1 ]
Volin, L [1 ]
Ruutu, P [1 ]
机构
[1] NATL PUBL HLTH INST,HELSINKI,FINLAND
关键词
inactivated poliovirus vaccine; BMT recipients;
D O I
10.1038/sj.bmt.1700959
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Forty-five adult HLA-matched sibling BMT recipients were randomized to receive inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months (early group, n = 23) or at 18, 20 and 26 months after BMT (late group, n = 22), Ninety-five percent of the early group patients had protective antibody titres of greater than or equal to 4 to poliovirus type 1 (PV1), poliovirus type 2 (PV2) and poliovirus type 3 (PV3) by a microneutralization assay prior to the first vaccination, at 6 months after BMT, The corresponding proportion for the late group patients was only 67% at 18 months, The antibody responses 1 month after each of the three IPV doses were similar in the two vaccination groups, except that four-fold responses occurred more frequently after the first dose to PV2 and PV3 in the late group, All patients had a protective antibody titre to all poliovirus serotypes 1 and 22 months after the third vaccine dose, except one patient in the early group who lacked antibodies to PV3 at 22 months, Acute GVHD accelerated the decrease of poliovirus antibody titres prior to vaccination but had no influence on vaccination response, Chronic GVHD neither influenced the patient's ability to retain poliovirus antibodies prior to vaccination nor impaired responses to vaccinations, A vaccination schedule consisting of three IPV doses was equally immunogenic when started at 6 or 18 months after allogeneic BMT.
引用
收藏
页码:663 / 668
页数:6
相关论文
共 22 条
  • [1] ALBRECHT P, 1984, REV INFECT DIS, V6, P540
  • [2] ANNETT G, 1994, BLOOD, V84, pA250
  • [3] ENGELHARD D, 1991, BONE MARROW TRANSPL, V8, P295
  • [4] POLYSACCHARIDE CONJUGATE VACCINE RESPONSES IN BONE-MARROW TRANSPLANT PATIENTS
    GUINAN, EC
    MOLRINE, DC
    ANTIN, JH
    LEE, MC
    WEINSTEIN, HJ
    SALLAN, SE
    PARSONS, SK
    WHEELER, C
    GROSS, W
    MCGARIGLE, C
    BLANDING, P
    SCHIFFMAN, G
    FINBERG, RW
    SIBER, GR
    BOLON, D
    WANG, M
    CARIATI, S
    AMBROSINO, DM
    [J]. TRANSPLANTATION, 1994, 57 (05) : 677 - 684
  • [5] HOVI T, 1986, LANCET, V1, P1427
  • [6] LIVOLTI S, 1994, BONE MARROW TRANSPL, V14, P225
  • [7] EFFICACY AND SAFETY OF VACCINATION OF MARROW TRANSPLANT RECIPIENTS WITH A LIVE ATTENUATED MEASLES, MUMPS, AND RUBELLA VACCINE
    LJUNGMAN, P
    FRIDELL, E
    LONNQVIST, B
    BOLME, P
    BOTTIGER, M
    GAHRTON, G
    LINDE, A
    RINGDEN, O
    WAHREN, B
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (04) : 610 - 615
  • [8] LJUNGMAN P, 1995, BONE MARROW TRANSPL, V15, P455
  • [9] LJUNGMAN P, 1991, BONE MARROW TRANSPL, V7, P89
  • [10] RESPONSE TO TETANUS TOXOID IMMUNIZATION AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
    LJUNGMAN, P
    WIKLUNDHAMMARSTEN, M
    DURAJ, V
    HAMMARSTROM, L
    LONNQVIST, B
    PAULIN, T
    RINGDEN, O
    PEPE, MS
    GAHRTON, G
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (02) : 496 - 500